is...Long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How the mighty have fallen, just two years ago $220 per share now only $11.56 The writing is on the wall as they well know.
"Novocure’s plan to reduce residual operating expenses by approximately $60 million includes a planned reduction in headcount of approximately 200 colleagues, 13% of its current workforce. Field-based commercial and field-based medical employees are minimally affected. Novocure expects to incur one-time costs related to the workforce reduction of approximately $7 million in the fourth quarter of 2023"
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 28, 2023
How the might have fallen, just two years ago $220 per share. The writing is on the wall as they well know.
"Novocure’s plan to reduce residual operating expenses by approximately $60 million includes a planned reduction in headcount of…
I have sent the following post to
UCLA Neurosurgery 🧠
@UCLANsgy
@UCLANsgy
— Peter Davis (@peter_brit) November 28, 2023
Please be advised there has been an attempt to attack Dr Liau's Phase 3 results by the following four Doctors. The accusations are factually incorrect and seriously flawed however, in case you are not aware of the attack I thought It best to let you know. I have… pic.twitter.com/728c8aoGeX
Perhaps purposefully delayed in the hope to have a huge impact/maximum damage just as Regulatory submissions occur ? Not on Team NWBO's watch 🤣
I cannot be certain but there are some interesting dates in the pdf version of the article:-
XX(XX), 1–15, 2023 | https://doi.org/10.1093/neuonc/noad211 | Advance Access date 23 November 2023
https://tinyurl.com/2duevvze
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 28, 2023
Not wanting him to feel left out, another author of the disgraceful 'hit piece' against DCVax® has a conflict of interest that he did not disclose. Ethan Chen is one of the authors involved in this gene therapy targeting #gbm along with other…
@EAChiocca #dcvax #allsolidtumors #gbm
— Peter Davis (@peter_brit) November 28, 2023
In your incorrect and flawed accusations, you also fail to mention that the trial endpoints were in fact pre-specified and changed prior to unblinding or was you aware of this and yet still chose to criticize a redundant endpoint and if… pic.twitter.com/NGKAuiFMm5
Previous challenges DC Vaccines were TME & difficulties in manufacturing which made other off-the-shelf approaches more attractive. However, you had the benefit of targeting multiple antigens, low AE profile. Now you have combination trials and companies like #NWBO addressing https://t.co/MqDM0MpfuR pic.twitter.com/ji6egJ4BS4
— Future (@Doc_Hieu) November 28, 2023
Marks: FDA open to using single-arm studies for accelerated approval of rare disease gene therapies
#dcvax #allsolidtumors $nwbo #gbm https://t.co/C0tuXaplvv pic.twitter.com/nBcVEreMvv
— Peter Davis (@peter_brit) November 28, 2023
They also (like so many others) fail to clarify that in fact the 'crossover' was FDA mandated or made any reference to all the measures proving efficacy despite pseudo-progression for example the work of Dr Steven Brem and his team or the complexities of the analysis of external controls undertaken including sensitivity analysis
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noad211/7444576?login=true
Gregory Zivic, MD
@metacollectiveG
"These Harvard folks had a DC based vaccine and it failed in early trials because NWBO came up with a patented way to make more pure Dendritic Cells. NWBO also has the ability to scale the manufacturing for a personalized autologous treatment; never done before in history"
#dcvax #allsolidtumors $nwbo #gbm https://t.co/DZIcsQ6zkl
— Peter Davis (@peter_brit) November 27, 2023
"There are no other cancer vaccines coming with more clear data. You’re wrong. B. There will be additional Real World Evidence supporting NWBOs NDAs. Academia can pretend to cloud things all they want, patients don’t give a rat’s ass; they want safe, non toxic treatments"
#dcvax #allsolidtumors $nwbo #gbm https://t.co/QJUoO6Yy5Z
— Peter Davis (@peter_brit) November 27, 2023
Gregory Zivic, MD
@metacollectiveG
"The mOS is statistically significant and that’s for all comers. Certain biomarkers can make it a cure. There is nothing else that extends life in TGBM. None. The manufacturing system they’ve developed will probably make the treatment under $100K, maybe $50K. They’ll pay
#dcvax #allsolidtumors $nwbo #gbm https://t.co/sfxaryzzCw
— Peter Davis (@peter_brit) November 27, 2023
Gregory Zivic, MD
@metacollectiveG
"Most of us believe there’ll be 2 stimuli before cash flow; Big Pharma paying up front $ for combination trials (See Dr. Liau’s combo trials at UCLA with Keytruda and Poly ICLC) and large Fund buy in. But approval in UK I’d say 2 months; they’re already manufacturing there=revenue"
Gregory Zivic, MD
@metacollectiveG
"NWBO speaks softly but is wielding a big stick. They’ve built the infrastructure almost in silence. I believe the reveal on this front will be striking. The proteonomic presentation by Dr Bosch got the eyes and ears of industry. In this game one wins by seeing what others ignore"
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/QJZkknHHdg
— Peter Davis (@peter_brit) November 27, 2023
I have sent an e-mail with link to the article along with my recent additional information on the conflicts of interest by authors however, it has to be said. I would hope the company are already fully aware and taking action but previously when I have passed on similar information, my e-mails have just been ignored. What is important in all cases is that the company are aware and obviously they are ultimately responsible for protecting the technology from all forms of attack,
It seems that another author of the NWBO 'hit piece' Alex Ling seems a little shy about revealing any conflicts of interest frequently posting "None" in his articles however, his research work clearly aligns his interests to treatments in glioblastoma in competition with DCVax particularly with "oncolytic viral therapies in glioblastoma" Speaks volumes...
As well as David Reardon and his relations to Chiocca Lab (as The Danish Dude has pointed out) we can see E.Antonio Chiocca (another author of the disgraceful 'hit piece' against DCVAX has similar links. His selfish conflicts of interest do not excuse his and the others of the purposeful lies in the article!
Also many of his conflicts of interest serve as direct competitors to the treatments that DCVax® can provide
Amacathera
https://www.amacathera.ca/pipeline
Bionaut labs
https://bionautlabs.com/pipeline
Genenta Inc
https://www.genenta.com/our-pipeline/
DNAtrix Inc
https://www.dnatrix.com/pipeline/
Seneca
https://www.senecatherapeutics.com/pipeline
He has equity options in:-
Bionaut Laboratories
see above
DNAtrix Inc
see above
Immmunomic therapeutics
https://www.immunomix.com/pipeline/
Seneca Therapeutics
see above
Ternalys Therapeutics
https://ternalys.com/our-science/
Applicable to broad range of intractable cancers and non-oncologic targets.
Synergistic with and enabling of other existing and experimental therapies.
He is co-founder and Board of Directors of Ternalys Therapeutics
He is named inventor on patents related to oncolytic viruses,,,These patents have been licensed to Candel Therapeutics inc
E.A.C. is an advisor to Amacathera, Bionaut Labs, Genenta, Inc., Insightec, Inc., DNAtrix Inc., Seneca Therapeutics, Theravir. He has equity options in Bionaut Laboratories, DNAtrix, Immunomic Therapeutics, Seneca Therapeutics, and Ternalys Therapeutics. He is co-founder and on Board of Directors of Ternalys Therapeutics. He is named inventor on patents related to oncolytic viruses under the possession of Brigham and Women’s Hospital (BWH).
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noad211/7444576
I also found it interesting that he also does not disclose he is a 'Founding Scientific Advisory Board member' of Alpheus Medical (along with Dr Roger Stupp)
Alpheus Medical
@alpheusmedical
[b"]Excited to announce our Phase 1 #glioblastoma #clinicaltrial for non-invasive #sonodynamictherapy is now enrolling. We also received #FDA Orphan Drug and Fast Track designations"
Learn how we aim to beat #braincancer.
https://rb.gy/dcuowd
#GBM #BTSM
Excited to announce our Phase 1 #glioblastoma #clinicaltrial for non-invasive #sonodynamictherapy is now enrolling. We also received #FDA Orphan Drug and Fast Track designations.
— Alpheus Medical (@alpheusmedical) July 13, 2022
Learn how we aim to beat #braincancer. https://t.co/Af7YFzZwLV#GBM #BTSM
Actually as well as financial compensation, only serious jail time will suffice and perhaps serve as a stark warning and deterrent to these criminals. They need to be taught a lesson 'if you can't do the time, don't do the crime'
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/AUqIYxRdCf
— Peter Davis (@peter_brit) November 27, 2023
I don’t mean it as gaslighting. I’m simply saying the evidence for what they have is easily seen. It’s my belief, based on what they’ve said in print, in SEC filings, in various trials, in updates on manufacturing, etc. that big money is in the wings awaiting filing of the MAA.
— Gregory Zivic, MD (@metacollectiveG) November 25, 2023
Gregory Zivic, MD
@metacollectiveG
"Opportunity costs? $NWBO was ahead of its time and unlike others in that situation actually didn’t throw in the towel when it appeared they were dead in the water like others did; they persevered and are on the cusp of the equivalent of developing air travel, or the wheel"
#dcvax #allsolidtumors $nwbo #gbm https://t.co/KcusnaBWbs
— Peter Davis (@peter_brit) November 26, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 26, 2023
In the full text pre-print awaiting 'Nature' peer-review:
'Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients'
There is further confirmation that 'ATL-DC' is in fact…
"Cohen Milstein...filed the Northwest Bio case with me you're going to see that ruling soon I think you're going to like it..."
— rj (@sharpie510) November 25, 2023
👏👏👏👏👏👏
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪#dcvax #glioblastoma #CitadelScandalhttps://t.co/POoA3NfKiP
"so having just a ‘small part’ is no comfort"
Perhaps no comfort to you but the fact is this is just part of a process, one in which the company does not have full control. Only those who choose to be 'blind' for their own agenda/reasons are ignoring the significant progress the company has now made getting us ready for approvals, and commercialization. Along with other work I expect they will update us in due course in relation to Flaskworks and plans for ramp up. We are literally a matter of weeks away from submission and without doubt folk need to put some perspective on where we are today. Sure there will be some who just want their profit now, are not interested in staying invested in the company and will never be happy what the company do until they get their profits however, there are also investors who realise that approvals in UK. US. Canada and Germany are just the very beginning of something incredible. Being so close to the start of application submissions after everything that has happened is truly remarkable. I say again, I am more than happy waiting another 2 or 3 weeks for this journey to continue it's progress and looking forward to the next development stage hand in hand with LL as part of our SAB to steer the company onwards to greater things.
Agreed. It is IMO purposefully 'veiled speech' however, when read carefully it points to the fact that there is actually only a small part of work still remaining. Also, note from this final paragraph:-
As described in the Company's prior update, it is anticipated that the publisher/QC team will need several weeks to complete their work on both the last portion of the MAA package and the integrated whole. Their work is independent of the Company.
It does not say they need "several weeks" more. they note what was stated in the "Company's prior update" As I have stated previously, I am happy for them to submit by 14th December and fully believe this will be achieved. It would also not be a surprise if we did not get the PR advising submission by the end of next week!
Of course, the company do not have to wait for MHRA approval before they submit applications to the other RA's so I fully accept from submission to March/April (my guess for MHRA approval is March), we will hear of submissions submitted to each of them also, good times ahead.😁
https://nwbio.com/northwest-biotherapeutics-provides-update-on-near-term-plans-for-submission-of-marketing-authorization-application-2/
Gregory Zivic, MD
@metacollectiveG
$NWBO The very people who created a biotech from scratch, completed a P3 trial, had it published in JAMA, created and refined mfg., got it approved, created astonishing patents, and is on the verge of getting approved by multiple RAs are being treated like shit. STOP!
#dcvax #allsolidtumors $nwbo #gbm https://t.co/EBsnQAvcOG
— Peter Davis (@peter_brit) November 23, 2023
I agree. Some folk make life so difficult for themselves. When I read the PR it is obvious that it is worded in such a way to confuse. They very obviously do not want to be tied to giving specific dates. I would guess to some extent they want an 'element of surprise' As far as I am concerned, I set my expectations that it will be submitted to MHRA no later than 14th December and likely before. After all these years I am seriously ok with this timeline, I believe it is realistic and acceptable. Those that are full of criticism and accusing Management of lying simply need to read the disclaimers provided by the company with the PR's
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning plans for DCVax are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes, risks related to the Company’s ability to achieve timely performance of third parties, risks related to whether the Company’s products will be viewed as demonstrating safety and efficacy, risks related to the Company’s ongoing ability to raise additional capital, and other risks included in the Company’s Securities and Exchange Commission (“SEC”) filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company’s results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 22, 2023
UPDATE:
"That team is now under way on this final stage of their work.
As described in the Company's prior update, it is anticipated that the publisher/QC team will need several weeks to complete their work on both the last portion of the…
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 22, 2023
2023 list of articles by Linda Liau
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
P Karschnia, M Smits, G Reifenberger, E Le Rhun, BM… pic.twitter.com/plOLtVD3DI
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/CbFze7B0mE
— Peter Davis (@peter_brit) November 22, 2023
#dcvax #allsolidtumors $nwbo #GBM $NWBO "DC are better ! but this is still interesting"https://t.co/dwqsRVZ1GF https://t.co/SHHavBQMUl
— Peter Davis (@peter_brit) November 22, 2023
Not necessarily, although it is important for us to uplist at some point. Judging by LL's comments at the last ASM, the company have this under consideration and are awaiting the right conditions. I do not believe that the uplisting by itself would stop the manipulation.
Excellent post! My opinion is that it would take one of three possible 'events' to take place to curtail the manipulation, these being:-
1. Approvals
2. The court ordering the seven MM's to stop their short trades
3. News of major partnership (s) with significant financing
I believe these would put us on a better footing and allow for a more realistic valuation.
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 21, 2023
The full text of preprint article currently awaiting peer-review with 'Nature' journal:-
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients
Posted Date: September… pic.twitter.com/G5zGuI38KV